Analysis
GLP-1 Market Timeline 2025 to 2027: Every Event That Moved a Price
Twenty-two months that reset this market: the shortage declared over, enforcement discretion ended, Novo suing and then settling with Hims, two oral GLP-1s approved, bran
Twenty-two months that reset this market: the shortage declared over, enforcement discretion ended, Novo suing and then settling with Hims, two oral GLP-1s approved, brand prices collapsing, and Medicare opening at $50. Each entry carries its date and whether we read the primary source. One widely circulated timeline records the Foundayo approval as a Complete Response Letter; the approval letter is dated 1 April 2026.
The timeline
| Date | Event | Effect on price | Evidence |
|---|---|---|---|
| Feb–May 2025 | FDA declares the semaglutide and tirzepatide shortages resolved; enforcement discretion ends for every class of compounder | Removes the shortage pathway. The surviving route requires a prescriber to document a clinical difference for the individual patient | Federal record |
| Sep 2025 | First large warning-letter wave, roughly 80 letters | Marketing claims, not dispensing. Several named platforms exit compounding | Federal record |
| Dec 2025 | Oral semaglutide approved — the Wegovy tablet | First approved oral for obesity. Self-pay $149 | Reported |
| 9 Feb 2026 | Novo Nordisk sues Hims & Hers | Patent infringement over a compounded semaglutide offering | Reported |
| 20 Feb 2026 | Second warning-letter wave, 30 letters | MEDVi and SkinnyRx named as recipients. Both are in this dataset | Reported |
| 9 Mar 2026 | Novo and Hims settle. Hims offers branded Novo products and stops marketing compounded GLP-1s | The largest telehealth platform exits compounding. Every comparison still listing a Hims compounded price is pricing something not sold | Reported, dated |
| Mar 2026 | Wegovy subscription route opens at about $249 a month via several platforms | Brand semaglutide undercuts many compounded programmes for the first time | Reported |
| 1 Apr 2026 | Foundayo (orforglipron) approved under NDA 220934 | Daily pill, no food or water restriction. Self-pay $149. 12.4% mean weight loss in ATTAIN-1 | FDA approval letter, read by us |
| 6 Apr 2026 | Foundayo begins shipping via LillyDirect | $25 with commercial coverage plus the savings card | Manufacturer announcement |
| 30 Apr 2026 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list | Live regulatory risk for 503B fulfilment. Section 503A is a separate pathway not addressed | Federal record |
| 8 Jun 2026 | Third warning-letter wave, 25 letters | Total passes 130 since late 2025 | Reported |
| 1 Jul 2026 | Medicare GLP-1 Bridge begins | $50 a month for eligible Part D enrollees on Wegovy, Zepbound or Foundayo. Prior authorisation required | Reported |
| 8 Jul 2026 | Idaho physician sentenced, 40 months, for signing telemedicine orders for patients never examined | Prosecutors said about 26 seconds per order | Reported |
| 16 Jul 2026 | CMS proposes barring Medicare payment for outsourced remote monitoring | Not final. Comments to 14 September 2026 | Federal record |
| 24 Jul 2026 | NAD: Willow Health permanently discontinues compounded semaglutide advertising claims after a Novo challenge | Fourth enforcement channel, alongside FDA letters, litigation and prosecution | Reported |
| 27 Jul 2026 | First provider in our dataset names its fulfilling pharmacies | NexLife (opens nexlife.us in a new tab) names five partners and discloses both 503A and 503B pathways | Provider's own pages, read by us |
| Jan 2027 | CMS Balance Model scheduled | Permanent Medicare GLP-1 coverage with value-based pricing | Reported, not yet in force |
One published timeline records the Foundayo event as a Complete Response Letter on 10 April 2026, and a guide library advertising 1,452 guides states the drug “is not yet available”.
The FDA approved it on 1 April 2026 under NDA 220934. We read the approval letter. There is a published label, a DailyMed listing and a manufacturer announcement. It shipped from 6 April.
The same timeline also describes the approval as the fastest since 2002. The approval letter records the application as received 20 January 2026 and approved effective on the date of the letter, which is a 71-day review.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What the twenty-two months actually did to prices
| Route | Late 2024 | July 2026 | What changed |
|---|---|---|---|
| Brand Zepbound | ~$1,060 | $299–$449 | LillyDirect self-pay vials |
| Brand Wegovy | ~$1,349 | $349 | NovoCare direct |
| Approved oral | did not exist | $149 | Two approvals in four months |
| Compounded tirzepatide, flat | ~$400+ | $186 | Competition, and the end of the shortage premium |
The direction that surprises people: brand fell faster than compounded. An approved product with its own trial programme now sits within a few dollars of the cheapest compounded programme we have captured. Most comparison pages still describe compounded as the budget option because they were written when that was true.
What to expect next, and what we will not predict
Two things are scheduled: the CMS comment period closes 14 September 2026, and the Balance Model is slated for January 2027. Both are proposals, and proposals change.
The unresolved 503B bulks proposal is the single largest open risk to compounded supply, and almost no provider addresses what happens to a prepaid balance if supply is interrupted. That is a question worth asking before you commit to a twelve-month plan, and it is on our commitment terms field page because almost nobody answers it.
The six tests, applied to everyone
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Questions readers actually ask
When was Foundayo approved?
1 April 2026, under NDA 220934. It began shipping via LillyDirect on 6 April. A widely circulated timeline records a Complete Response Letter instead; the approval letter is public.
When did the Medicare GLP-1 Bridge start?
1 July 2026. Eligible Part D enrollees pay about $50 a month for Wegovy, Zepbound or Foundayo, with prior authorisation.
Did Novo Nordisk and Hims settle?
Yes, on 9 March 2026. Hims offers branded Novo products and stopped marketing compounded GLP-1s, so any comparison still listing a Hims compounded price is pricing a product that is not sold.
How many FDA warning letters have there been?
Three waves: roughly 80 in September 2025, 30 on 20 February 2026 and 25 on 8 June 2026. MEDVi and SkinnyRx are named recipients of the February wave.
Are brand GLP-1s still more expensive than compounded?
Not always. Brand Zepbound is $299 to $449 through LillyDirect and two approved pills are $149, against $186 for the cheapest flat compounded programme we have captured.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Ro Body Tirzepatide ReviewProviders
- PlushCare Tirzepatide ReviewProviders
- NexLife vs Hims & HersComparisons
- Mounjaro vs ZepboundPillar / Money
- Hims & Hers Tirzepatide ReviewProviders
- Zepbound vs MounjaroComparisons
- Tirzepatide Cost in 2026Pillar / Money
Related coverage
- GLP-1s and Knee Osteoarthritis: Real Pain Reduction, Unsettled Mechanism
- GLP-1 market timeline, every event checked
- 503A against 503B
- The 23 July compounding vote
- What a year actually costs
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Tirzepatide Telehealth in Iowa
- Tirzepatide Telehealth in Kansas
GLP-1 Tirzepatide Ranked. “GLP-1 Market Timeline 2025 to 2027: Every Event That Moved a Price.” S.J Partners LLC, 2026-07-26. https://glp1tirzepatideranked.com/journal/glp1-market-timeline-2025-2027/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.